Straits Times Index
3,134.87 -5.34 (-0.17%) Nikkei
26,723.66 -80.94 (-0.30%) Hang Seng
21,996.89 -422.08 (-1.88%) FTSE 100
7,312.32 -11.09 (-0.15%) BTC-USD
20,060.53 -186.81 (-0.92%) CMC Crypto 200
431.08 -8.59 (-1.95%)
Nuvation Bio Inc. (NUVB)
After hours:
| Previous close | 3.5500 |
| Open | 3.5200 |
| Bid | 3.1700 x 1800 |
| Ask | 3.3700 x 800 |
| Day's range | 3.4300 - 3.6000 |
| 52-week range | 3.2500 - 10.4500 |
| Volume | |
| Avg. volume | 979,317 |
| Market cap | 756.908M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.67 |
- Business Wire
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
NEW YORK, June 27, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company’s Phas
- Business Wire
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
NEW YORK, May 09, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.
- Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
NEW YORK, February 28, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
